Atorvastatin vs Rosuvastatin in the Prevention of Cardiovascular Events: A Systematic Review

The main objective of this study is to compare any differences in the clinical response to rosuvastatin and atorvastatin in patients with cardiovascular disease. PubMed, SCOPUS, Web of Science, Science Direct, and Clinical Key were systematically searched for relevant literature. Rayyan QRCI was employed throughout this comprehensive process. We included eleven studies with a total of 6168 patients; 3231 (52.4%) patients received Atorvastatin, and 2937 (47.6%) received Rosuvastatin. Regarding ACS patients, Rosuvastatin outperformed Atorvastatin in improving laboratory indices and inflammatory markers and lowering LDL. In STEMI patients undergoing PCI, Atorvastatin was linked to less dysfunctional coronary circulation, better coronary microcirculation in patients with STEMI having primary PCI, and may enhance microvascular coronary perfusion immediately following PCI more effectively than a high-dose rosuvastatin preloading. The one study included patients undergoing CABG and did not find any differences between Atorvastatin and Rosuvastatin in preventing post-CABG atrial fibrillation (AF). These results suggest that when developing treatment plans for patients with cardiovascular disease, physicians may be able to combine atorvastatin with rosuvastatin. Cost considerations, tolerability, and patient-specific characteristics should all be taken into account during the decision-making process.